SCHEMBL2657586

SCHEMBL2657586

O=C(Nc1nccs1)C(Oc1ccc(F)cc1F)c1ccc(S(=O)(=O)C2CCCCC2)cc1

nearest known ligand 0.65

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
GCK P35557 19/20 0.65
KCNH2 Q12809 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2657872 0.99 GCK (0.66) GCKKCNH2
SCHEMBL2657143 0.96 GCK (0.70) GCKKCNH2
SCHEMBL2656842 0.87 GCK (0.60) GCKKCNH2
SCHEMBL16456824 0.86 GCK (0.60) GCK
SCHEMBL2656416 0.85 GCK (0.73) GCK
SCHEMBL2657105 0.85 GCK (0.61) GCK
SCHEMBL2657590 0.85 GCK (0.48) GCKKCNH2
SCHEMBL2656974 0.85 GCK (0.60) GCK
SCHEMBL2657875 0.84 GCK (0.48) GCKKCNH2
SCHEMBL2657952 0.84 GCK (0.71) GCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2195304-B1 ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND MEDICINAL APPLICATIONS ADVINUS THERAPEUTICS PRIVATE LTD (IN) 2014-01-08 EP claimed
US-8501955-B2 Acetamide derivatives as glucokinase activators, their process and medicinal application ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) 2013-08-06 US claimed
US-20100310493-A1 ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND MEDICINAL APPLICATION ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) 2010-12-09 US claimed
EP-2195304-A2 ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND MEDICINAL APPLICATIONS Advinus Therapeutics Private Limited (IN) 2010-06-16 EP claimed
WO-2009047798-A2 ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND MEDICINAL APPLICATIONS ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) 2009-04-16 WO claimed
EP-2195304-B1 ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND MEDICINAL APPLICATIONS ADVINUS THERAPEUTICS PRIVATE LTD (IN) 2014-01-08 EP disclosed
US-8501955-B2 Acetamide derivatives as glucokinase activators, their process and medicinal application ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) 2013-08-06 US disclosed
US-20100310493-A1 ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND MEDICINAL APPLICATION ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) 2010-12-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100310493-A1 ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND MEDICINAL APPLICATION GCK, GCKR, ALDOA GCK 1/4885KCNH2 2446/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.